跳至主要内容
临床试验/NCT04343586
NCT04343586已完成不适用

Development & Preliminary Clinical Validation Blue Light Phototherapy Systems for T-Cell

Northwestern University2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2020年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
11
试验地点
2
主要终点
Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.

研究概览

简要总结

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient's aged 18-89 at time of enrollment
  • Previous diagnosis of psoriasis vulgaris or Grover's disease

排除标准

  • All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
  • Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
  • Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
  • topical steroids
  • calcineurin inhibitors
  • methotrexate
  • retinoids
  • biologic agents
  • Unable to schedule phototherapy sessions
  • We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

结局指标

主要结局

Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.

时间窗: Time Frame: 5 weeks

The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.

Efficacy of Blue Light Therapy for Patients With Grover's Disease

时间窗: Time Frame: 5 weeks

Demonstrate preliminary skin efficacy as measured by lesion count

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shuai (Steve) Xu

Principal Investigator

Northwestern University

研究点 (2)

Loading locations...

相似试验